Crescent Biopharma (CBIO) Reiterated at Buy by Stifel on CR-003/SKB105 Potential

June 23, 2026 6:58 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $30.00 price target on Crescent Biopharma Inc (NASDAQ: CBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found